Finally the US approved the first treatment for Lupus since 50 years. With this researchers have met a milestone as they have prepared a tiny biotech maker. Health officials believe that to combat the disease that causes the immune system to attack joints and organs and has proved tough to study and treat so far. The shares of human genome were halted and the company split profits with British drug giant GlaxoSmithKline. The shares of GSK rose to 3.4 percent and some analysts predict sales as $5 billion in later years. With new discoveries, and genius minds, this has opened way to FDA approved drugs. The US FDA has approved Benlysta for certain patients with active lupus who are receiving standard therapy. Although the study lacked few figures to establish a definite conclusion and warned to be used in black patients. They have approved the company to run a post approval study as well in blacks. The lupus patients with severe kidney or central nervous system problems are not recommended to undergo the treatment. The FDA required a patient friendly guide explaining the risks. The treatment might cause serious infections and deaths as compared with placebo in clinical studies.